Longboard Pharmaceuticals Inc.
- Address
- 4275 Executive Square Suite 950
Sponsor Overview
Specializations
Developmental and Epileptic Encephalopathies
Longboard Pharmaceuticals Inc. focuses on developmental and epileptic encephalopathies with studies aimed at seizure control in children and adults affected by severe early-onset epilepsy syndromes. Its research activity in this area centers on conditions marked by frequent motor seizures and substantial neurological impairment.
- Countable motor seizures
- Children and adults with DEE
- Epileptic encephalopathy
The sponsor’s clinical work in this field is directed toward therapeutic options for severe seizure disorders across multiple age groups and international research sites.
Dravet Syndrome
The company also studies Dravet syndrome, a rare and severe epileptic disorder associated with recurrent seizures and complex neurological burden. The sponsored research is centered on seizure reduction in both pediatric and adult populations.
- Seizure burden
- Pediatric and adult patients
- Rare epilepsy
This area of interest reflects a therapeutic emphasis on difficult-to-treat seizure disorders with substantial unmet medical need.
Neurology and Seizure Disorders
Longboard Pharmaceuticals Inc. is active in neurology through programs addressing severe seizure disorders and related central nervous system conditions. Its funded trials are concentrated on clinical outcomes relevant to seizure frequency and disease severity.
- Central nervous system disorders
- Severe epilepsy
- Neurological impairment
The sponsor’s research portfolio is aligned with therapies intended for patients whose epilepsy is associated with significant developmental and functional impact.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Efficacy and Safety of Bexicaserin Hydrochloride in Developmental and Epileptic Encephalopathies: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study |  Belgium Czechia Denmark Finland France Germany Italy Latvia Portugal Spain The Netherlands | Not Recruiting |
| Efficacy and Safety of Bexicaserin in Seizure Management for Pediatric and Adult Dravet Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study | Belgium Czechia Denmark Finland France Germany Italy Latvia Portugal Spain The Netherlands | Recruiting |
| Evaluation of Long-Term Safety and Efficacy of Bexicaserin (LP352) in Pediatric and Adult Patients with Developmental and Epileptic Encephalopathy | Belgium France Germany Italy Latvia Portugal Spain The Netherlands | Recruiting |
Data & Insights
This sponsor works with 0 molecules, of which 0 are not being studied by other sponsors.
This sponsor has worked with 49 sites across their trial portfolio.
Therapeutic Focus
- 1.Nervous System Diseases3 trials449 other sponsors
Partnered Research Centres
49 centres- Address
- Palle Juul-Jensens Boulevard 99, 8200 Aarhus
- Address
- 264 Rue Saint Pierre, 13005 Marseille
- Address
- Num Voie 47 A 83, 47 Boulevard De L Hopital, 75013 Paris
- Address
- Viale Gaetano Pieraccini 24, 50139 Florence
- Address
- Piazza Di Sant'onofrio 4, 00165 Rome
- Address
- Zemgales Priekspilseta, Vienibas Gatve 45, 1004 Riga
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Longboard Pharmaceuticals Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.